Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Wall Street Opens Higher on AstraZeneca Booster Shot; Dow up 215 Pts

Published 11/23/2020, 09:38 AM
Updated 11/23/2020, 09:50 AM
© Reuters.

By Geoffrey Smith 

Investing.com -- U.S. stock markets opened the week higher, on news that a third experimental vaccine to treat the Covid-19 vaccine had registered an effectiveness rate of 90% or more. That helped to mitigate concerns that the upcoming Thanksgiving holiday will only propel the current wave of the pandemic even more violently through the U.S.

By 9:40 AM ET (1440 GMT), the Dow Jones Industrial Average was up 215 points, or 0.7% at 29,478 points. The S&P 500 and the NASDAQ Composite were both up 0.6%.

On a light day for data, sentiment was mainly informed by the news that AstraZeneca's experimental drug had proven effective in up to 90% of cases, according to preliminary data from a late-stage trial. The message was slightly blunted by the company also saying that a parallel regimen in the test had shown a lower success rate of 62%. As the less effective regiment requires more vaccine resources of the two, it's not clear why the less effective regimen will be relevant going forward.  AstraZeneca (NASDAQ:AZN) ADRs were down 2.6% in early trade.

As with most releases on the progress of vaccine development, the news helped the stocks worst hit by this year's lockdowns and consumer fear of infection. The Dow Jones Airlines index rose 2.0%. while department store stock also leaped: Macy’s (NYSE:M) stock and Nordstrom (NYSE:JWN) stock both hit five-month highs, rising 6.7% and 5.2% respectively. Kohls (NYSE:KSS) stock rose 2.4% but failed to post a new high.

By the same token, stay-at-home stock suffered: Zoom Video (NASDAQ:ZM) stock fell 4.2% while Peloton Interactive (NASDAQ:PTON) stock fell 3.2%. Big Tech names such as Apple (NASDAQ:AAPL), Alphabet (NASDAQ:GOOG) and Facebook (NASDAQ:FB) all edged down slightly, as money that had sought safety in such names earlier in the year ventured out in search of more attractively-valued ones.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Analysts at Goldman Sachs (NYSE:GS) said in a strategy note that they expect the rotation into cyclical and value stocks to continue broadly, if not smoothly, as hopes for a global economic rebound in 2021 solidify.

"We would use any volatility to re-risk as markets are likely to focus increasingly on the recovery next year," global equity strategy chief Christian Mueller-Glissmanm wrote.

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.